Prima BioMed has received endorsement from the European regulator (EMA) for its planned Phase IIb trial of IMP321 in metastatic breast cancer (MBC). The primary endpoint is progression free survival. Our valuation and financial forecasts are under review pending funding resolution at the upcoming EGM and completion of the ongoing share purchase plan (SPP).
